This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus (BALANCE)

This study has been completed.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: May 4, 2010
Last updated: June 5, 2015
Last verified: June 2015
Evaluate the efficacy, safety and tolerability of a 12-week treatment of 4 doses of ASP1941 compared to placebo in combination with metformin in adult patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin alone.

Condition Intervention Phase
Type 2 Diabetes Mellitus Drug: ASP1941 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase IIb, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12-Week Treatment With ASP1941 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Change from baseline in HbA1c at Week 12 [ Time Frame: Baseline, 12 weeks ]

Secondary Outcome Measures:
  • Change from baseline in fasting plasma glucose (FPG) at Week 12 [ Time Frame: Baseline, 12 weeks ]
  • Achievement of target goal (HbA1c <7.0%) at Week 12 [ Time Frame: 12 weeks ]
  • Achievement of target goal (HbA1c <6.5%) at Week 12 [ Time Frame: 12 weeks ]

Enrollment: 343
Study Start Date: April 2010
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ASP1941 lowest dose Drug: ASP1941
oral tablet
Experimental: ASP1941 low dose Drug: ASP1941
oral tablet
Experimental: ASP1941 high dose Drug: ASP1941
oral tablet
Experimental: ASP1941 highest dose Drug: ASP1941
oral tablet
Placebo Comparator: Placebo Drug: Placebo
oral tablet


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has been diagnosed with Diabetes Mellitus type 2 (T2DM) for at least 6 months
  • Subject has inadequate glycemic control indicated by an HbA1c level between 7.0% and 9.5% at start of the run-in period at Visit 1 AND does not meet any of the FPG discontinuation criteria
  • Subject has been on a stable dose of at least 1500 mg/day metformin monotherapy for at least 6 weeks prior to Visit 1
  • Subject is on a stable diet and exercise program (for at least 6 weeks prior to Visit 1) and is willing to remain on this program for the duration of the study
  • Subject has a body mass index (BMI) 20 - 45 kg/m2 at Visit 1
  • Female subject of childbearing potential has a negative serum pregnancy test (human chorionic gonadotropin [hCG]) at Visit 1 and agrees to use an acceptable form of contraception throughout the duration of the study OR is at least 1 year post-menopausal (defined as amenorrhea for at least 1 year) or surgically sterile. Male study subjects should be advised to use a male condom in addition to having their partner use another acceptable method during the study and for 3 months after the last dose

Exclusion Criteria:

  • Subject has any known complication of T2DM indicating a late disease state that in the investigator's opinion should preclude the subject from participation
  • Subject has type 1 diabetes mellitus
  • Subject is in need of insulin therapy or has received insulin within 3 months prior to Visit 1, with the exception of acute use of <7 days
  • Subject has a serum creatinine higher than upper limit of normal range at Visit 1
  • Subject has an alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) higher than 3 times upper limit of normal range or has a total bilirubin more than 2 times upper limit of normal at Visit 1
  • Subject has a urinary microalbumin/creatinine ratio above or equal to 300 mg/g at Visit 1
  • Subject has a symptomatic urinary tract infection (UTI) or symptomatic genital infection at Visit 1 or during the placebo run-in period, including just prior to randomization at Visit 2
  • Subject has persistent, uncontrolled severe hypertension as indicated by a systolic blood pressure >180 mmHg or a diastolic blood pressure of >110 mmHg taken in a sitting position after 5 minutes of rest on at least 2 measurements (within 30 minutes of each other) at Visit 1
  • Subject has a significant cardiovascular disease, such as myocardial infarction or a vascular intervention (e.g. angioplasty or stent) within 3 months prior to Visit 1, or history of heart failure (New York Heart Association [NYHA] Class III IV)
  • Subject is known to have hepatitis or be a carrier of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody (enzyme linked immunosorbent assay [ELISA] plus confirmatory test), or is known positive for human immunodeficiency virus (HIV) HIV-1 and/or HIV 2
  • Subject is currently receiving an excluded medication (loop-diuretics or systemic corticosteroids) or has received any other oral anti-diabetic drug except for metformin within 3 months prior to Visit 1
  • Subject has history of lactic acidosis
  • Subject has a history of drug or alcohol abuse/dependency within 12 months prior to Visit 1 as defined in the Diagnostic and Statistical Manual-IV (DSM-IV)
  • Subject has had a malignancy in the last 5 years, except for adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
  • Female subject who is pregnant, lactating or pre-menopausal with positive serum pregnancy test (hCG) at Visit 1 or has an intention of becoming pregnant
  • Subject has an unstable medical or psychiatric illness
  • Subject has known or suspected hypersensitivity to ASP1941 or any components of the formulations used
  • Subject has previously received ASP1941
  • Subject is concurrently participating in another drug study or has received an investigational drug within 30 days (or the limit set by national law, whichever is longer) prior to Visit 1
  • Subject has any concurrent illness which, in the opinion of the investigator, may interfere with treatment or evaluation of safety or completion of this study
  • In the investigator's judgment, the subject is unable to adhere to the treatment regimen, protocol procedures or study requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01117584

  Hide Study Locations
United States, California
Los Angeles, California, United States, 90036
United States, Florida
Coral Gables, Florida, United States, 33134
Hialeah, Florida, United States, 33012
Kissimmee, Florida, United States, 34741
United States, Nevada
Las Vegas, Nevada, United States, 89106
Baja, Hungary, 6500
Balatonfured, Hungary, 8230
Budapest, Hungary, 1036
Budapest, Hungary, 1076
Gyongyos, Hungary, 3200
Mako, Hungary, 6900
Nyiregyhaza, Hungary, 4400
Zalaegerszeg, Hungary, 8900
Ancona, Italy, 60100
Milan, Italy, 20132
Sienna, Italy, 53100
Chrzanow, Poland, 32-500
Katowice, Poland, 40-752
Krakow, Poland, 30-015
Krakow, Poland, 30-550
Kutno, Poland, 99-330
Lodz, Poland, 90-302
Lublin, Poland, 20-044
Warszawa, Poland, 03-003
Wroclaw, Poland, 50-127
Wroclaw, Poland, 50-349
Brasov, Romania, 500269
Brasov, Romania, 500365
Bucharest, Romania, 010492
Bucharest, Romania, 011234
Bucharest, Romania, 020475
Bucuresti, Romania, 020275
Bucuresti, Romania, 020475
Bucuresti, Romania, 20045
Constanta, Romania, 900675
Craiova, Romania, 200642
Lasi, Romania, 700547
Ploiesti, Romania, 100018
Ploiesti, Romania, 100163
Sibiu, Romania, 550245
Sibiu, Romania, 550371
United Kingdom
Birmingham, United Kingdom, B15 2SQ
Cambridgeshire, United Kingdom, CB8 9PW
Manchester, United Kingdom, M15 6SX
Reading, United Kingdom, RG2 0TG
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Ude Central Contact Astellas Pharma Europe B.V.
  More Information

Additional Information:
Responsible Party: Astellas Pharma Inc Identifier: NCT01117584     History of Changes
Other Study ID Numbers: 1941-CL-0005
2009-013881-25 ( EudraCT Number )
Study First Received: May 4, 2010
Last Updated: June 5, 2015

Keywords provided by Astellas Pharma Inc:
Type 2 diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on August 23, 2017